/
KPRX
$2.61+$0.07 (+2.76%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$11.3M
4M shares
52-week range
$1.76 – $3.29
55% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.43%
Moderate
Price (6 mo)
Loading chart…
Change$-652.59
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $2.7M | $12.1K | $0 | $0 | $0 | $16.0M | $0 |
| Cost of revenue | $8.1M | $4.9K | $3.3M | $0 | $0 | $0 | $0 | $24.8K |
| Gross profit | −$6.4M | $2.7M | −$3.3M | $0 | $0 | $0 | $16.0M | −$24.8K |
| Gross margin | -387.5% | 99.8% | -27038.7% | — | — | — | 100.0% | — |
| R&D | $8.1M | $5.4M | $3.6M | $5.4M | $3.4M | $4.0M | $4.9M | $10.8M |
| Operating income | −$10.8M | −$7.0M | −$6.9M | −$14.2M | −$12.3M | −$12.6M | $4.5M | −$9.5M |
| EBITDA | −$10.7M | −$6.8M | −$7.5M | −$13.9M | −$13.6M | −$12.4M | $5.7M | −$12.1M |
| Net income | −$10.8M | −$7.1M | −$6.9M | −$13.8M | −$13.6M | −$12.5M | $3.6M | −$10.8M |
| Net margin | -654.2% | -264.2% | -56901.7% | — | — | — | 22.5% | — |
| EPS (diluted) | -182.81 | -89.24 | -70.50 | -68.00 | -18.55 | -24.25 | 0.87 | -2.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-2.66 | $-2.66–$-2.66 | 1 |
| 2027 | $29M | $-1.03 | $-1.03–$-1.03 | 1 |
| 2028 | $23M | $-1.15 | $-1.15–$-1.15 | 1 |
| 2029 | $57M | $1.05 | $1.05–$1.05 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.55
Price
$2.61
Implied downside
-2%
Peer comparison
Kiora Pharmaceuticals, Inc. Common Stock
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
www.kiorapharma.com- Employees
- 13
- IPO / List date
- Feb 13, 2015
- HQ
- ENCINITAS, CA
Held by traders on TradeandTell
No one on the platform currently holds KPRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 21,200 | $41.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-06-11 | 1-for-9reverse |
| 2022-09-27 | 1-for-40reverse |
| 2019-08-30 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded KPRX yet.
